## AZN: AstraZeneca PLC - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.04 indicates fundamental undervaluation. Quality metrics strong (ROE 22%). Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($88.55)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 7
- **Sentiment:** Neutral (Bullish: 2, Bearish: 2)

**1. AstraZeneca Sues US Over Drugs for Medicare Price Cuts Round 2**
- Source: Bloomberg Law News | 20251222T170925 | Bearish | Relevance: 100%
- AstraZeneca has filed a lawsuit against the US government, challenging the Centers for Medicare & Medicaid Services' determination of drugs eligible for Medicare price negotiations. The pharmaceutical giant's complaint alleges that the definition of "qualifying single source drugs" under the Biden-era plan is unlawful, especially after one of its cancer treatments was selected for the program's second cycle. The lawsuit focuses on the eligibility criteria for high-cost, brand-name drugs without generic competition to be included in the price negotiation scheme.

**2. AstraZeneca (AZN) gains 10th FDA Breakthrough Therapy nod for Enhertu in HER2-positive early breast cancer**
- Source: Stock Titan | 20251222T120925 | Bullish | Relevance: 100%
- AstraZeneca's Enhertu, co-developed with Daiichi Sankyo, has received its tenth US FDA Breakthrough Therapy Designation. This latest designation is for Enhertu as a post-neoadjuvant treatment for adults with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant therapy and are at high risk of recurrence, based on positive Phase III DESTINY-Breast05 trial results. This designation underscores Enhertu's strategic importance in AstraZeneca's oncology portfolio and aims to accelerate its development and review for this significant unmet medical need.

**3. AstraZeneca PLC - Update on LATIFY Phase III trial of ceralasertib**
- Source: Research Tree | 20251222T120925 | Somewhat-Bearish | Relevance: 100%
- AstraZeneca's LATIFY Phase III trial for ceralasertib combined with Imfinzi in previously treated advanced non-small cell lung cancer did not meet its primary endpoint of overall survival. Despite the disappointing results, the combination was generally well-tolerated, and the company remains committed to developing new medicines for lung cancer. The data from the trial will be presented at a future medical meeting.

**4. REG - AstraZeneca PLC - Director/PDMR Shareholding**
- Source: TradingView — Track All Markets | 20251222T110925 | Neutral | Relevance: 100%
- AstraZeneca PLC announced a transaction involving Nazneen Rahman, a Non-Executive Director. On December 18, 2025, Ms. Rahman sold 297 Ordinary Shares of $0.25 each at a price of £134.96 per share. This notification is made in accordance with the EU Market Abuse Regulation requirements.

**5. AstraZeneca Refuels KRAS Push With Jacobio Partnership For Pan-Inhibitor**
- Source: Citeline News & Insights | 20251222T070925 | Bullish | Relevance: 100%
- AstraZeneca is increasing its focus on pan-KRAS inhibitors through a new partnership with Jacobio Pharmaceuticals. This collaboration aims to accelerate AstraZeneca's efforts in developing treatments for KRAS-mutated cancers. The move signals AstraZeneca's continued commitment to this challenging area of oncology research.

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 10.3% |
| Smart Money | **BEARISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Price (T.Rowe) Assoc: 1.9% (-5.4%)
- Primecap Management : 1.5% (-3.3%)
- Bank of America Corp: 1.2% (+4.7%)
- Wellington Managemen: 1.2% (-5.9%)
- Capital Internationa: 0.9% (-20.2%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.04 suggests fair value with growth premium. Quality metrics strong (ROE 22%, margin 16%). Balance sheet: $4.4B free cash flow. Institutional flow bearish (6 selling vs 4 buying).

| Metric | Value |
|--------|-------|
| Market Cap | $283.9B |
| Beta | 0.17 |
| 52W Range | $61.24 - $94.02 |
| Short Interest | 0.3% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.04 |
| Forward P/E | 17.8 |
| Current P/E | 19.9 |
| YoY Growth | 12.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 weakening modestly (-0.8% over 5 days). Below STRENGTH zone by 4.1pp (needs >4.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 57. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.08% (CS: 46) | Neutral |
| RSI_14 | 57.4 | Neutral |
| MACD Histogram | -0.21 | Bearish |
| vs SMA20 | 1.005x | Above |
| vs SMA50 | 1.046x | Above |
| vs SMA200 | 1.185x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $91.55
- **Stop Loss:** $88.55 (3.3% risk)
- **Target:** $97.55 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 400
- **Position Value:** $36,620.00
- **Portfolio %:** 36.62%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-10 (Est: $1.09)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.13 | $1.19 | +4.9% |
| 2025Q2 | $1.46 | $1.08 | -25.9% |
| 2025Q1 | $1.12 | $1.25 | +11.6% |
| 2024Q4 | $1.04 | $1.04 | +0.8% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*